BACKGROUND
Borderline resectable and locally advanced pancreatic ductal adenocarcinoma remains associated with high local recurrence despite modern neoadjuvant therapy and surgery. Intraoperative…
consecutive adult patients who received 2–6 months of neoadjuvant mFOLFIRINOX or GnP followed by pancreatectomy for localized PDAC from 2010–2018. Patients were drawn from 16 high-volume centers…
BACKGROUND
Up to 40% of patients undergoing pancreatoduodenectomy (PD) for resectable pancreatic ductal adenocarcinoma do not receive adjuvant chemotherapy (aCT). This study aimed to evaluate the…
BACKGROUND
While numerous studies have evaluated predictors of postoperative pancreatic fistula (POPF) after pancreatectomy, limited data exist regarding the impact of neoadjuvant chemotherapy (NAC)…
BACKGROUND
In recent years, neoadjuvant therapy (NAT) has received growing interest and is now the standard of care for borderline resectable (BR) pancreatic cancer (PC) and locally advanced (LA) PC.…
BACKGROUND
The prognostic utility of CA19-9 may vary based on the clinical and genetic factors (e.g., FUT2/FUT3 mutation or UGT1A1 alleles). We sought to examine early post-operative changes in…
Background/Aims
Clinical data on chemotherapy outcomes in older patients with pancreatic cancer are limited. This population-based study aimed to evaluate the effects of chemotherapy on survival…
BACKGROUND
The survival benefit of neoadjuvant chemotherapy (NAC) in early-stage pancreatic ductal adenocarcinoma (PDAC) remains uncertain. Although retrospective studies often suggest improved…
Pancreatic adenosquamous carcinoma (PASC) is a rare exocrine malignancy of the pancreas with an increasing incidence, histologically defined by the coexistence of adenocarcinoma and squamous…
BACKGROUND
Pancreatic ductal adenocarcinoma (PDAC) is a major cause of cancer-related deaths in Australia, with a 5-year survival rate of less than 13%. The liver is the most common site of PDAC…